Compositions and methods for vaccination against influenza A virus
Disclosed herein are compositions and methods useful for immunizing a subject against disease caused by influenza A. Disclosed methods comprise administering to the subject an immunoprotective dose of an immunogenic composition. In certain aspects, the immunogenic composition is a vaccine comprised of a recombinant chimeric hemagglutinin polypeptide. In certain aspects, the subject is a mammal. In further aspects, the mammal is a pig. In still further aspects, the mammal is a human.
1. An immunogenic composition comprising a polypeptide comprising the sequence of SEQ ID NO 8.
2. The immunogenic composition of claim 1 , wherein the immunogenic composition is a recombinant polypeptide.
3. The immunogenic composition of claim 2 , further comprising a vector.
4. The immunogenic composition of claim 3 , wherein the vector further comprises a virus backbone.
5. The immunogenic composition of claim 4 , wherein the virus backbone is PR8 LAIV or TX98.
6. The immunogenic composition of claim 4 , wherein the virus backbone is a non-influenza virus.
7. The immunogenic composition of claim 6 , wherein the virus backbone is retrovirus, lentivirus, adenovirus, adeno-associated virus, or parainfluenza virus.
8. The immunogenic composition of claim 3 , further comprising an adjuvant.
9. The immunogenic composition of claim 3 , further comprising a pharmaceutically acceptable carrier.
10. A method of immunizing a subject against disease caused by influenza A comprising administering to the subject an immunoprotective dose of an immunogenic composition, wherein the immunogenic composition comprises: a polypeptide comprising the sequence of SEQ ID NO 8.
11. The method of claim 10 , wherein the subject is a mammal.
12. The method of claim 11 , wherein the mammal is a pig.
13. The method of claim 11 , wherein the mammal is a human.
14. The method of claim 10 , wherein the immunogenic composition is a recombinant polypeptide.
15. The method of claim 10 , wherein the immunogenic composition further comprises a virus backbone.
16. The method of claim 14 , wherein the virus backbone is a non-influenza virus.
17. The method of claim 16 , wherein the non-influenza virus is a retrovirus, lentivirus, adenovirus, adeno-associated virus, or parainfluenza virus.
18. The method of claim 14 , wherein the immunogenic composition is an attenuated virus.